ArriVent BioPharma (AVBP) Common Equity (2023 - 2026)
ArriVent BioPharma (AVBP) posted Common Equity of $324.0 million for Q1 2026, up 5.45% sequentially from $307.2 million in Q4 2025, and up 59.96% YoY from $202.5 million in Q1 2025.
ArriVent BioPharma (AVBP) Common Equity (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Common Equity for 4 years, with the latest figure at $324.0 million in Q1 2026.
- Quarterly Common Equity rose 59.96% year-over-year to $324.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $324.0 million (up 59.96% YoY) and the FY2025 annual result came in at $307.2 million, up 19.24% from the prior year.
- Common Equity climbed to $324.0 million in Q1 2026 per AVBP's latest filing, from $307.2 million in the prior quarter.
- Over five years, Common Equity peaked at $324.0 million in Q1 2026 and troughed at -$153.2 million in Q4 2023.
- A 4-year average of $156.7 million and a median of $257.7 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity surged 427.25% in 2024, then slumped 36.25% in 2025.
- Over 4 years, Common Equity stood at -$153.2 million in 2023, then soared by 268.19% to $257.7 million in 2024, then climbed by 19.24% to $307.2 million in 2025, then climbed by 5.45% to $324.0 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $324.0 million, $307.2 million, and $305.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 366.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 366.84 Mn |
| Mar 31, 2026 | 323.98 Mn |
| Dec 31, 2025 | 307.22 Mn |
| Sep 30, 2025 | 305.00 Mn |
| Jun 30, 2025 | 249.87 Mn |
| Mar 31, 2025 | 202.54 Mn |
| Dec 31, 2024 | 257.65 Mn |
| Sep 30, 2024 | 277.49 Mn |
| Jun 30, 2024 | 296.66 Mn |
| Mar 31, 2024 | 317.72 Mn |
| Dec 31, 2023 | -153.19 Mn |
| Sep 30, 2023 | -132.60 Mn |
| Jun 30, 2023 | -118.46 Mn |
| Mar 31, 2023 | -97.09 Mn |